(Q36565032)

15 August 2017

1 reference

title

Cardiac dysfunction associated with trastuzumab (English)

1 reference

15 August 2017

Karen Lisa Smith

1

1 reference

15 August 2017

Chau Dang

series ordinal

2

1 reference

15 August 2017

Andrew D Seidman

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 September 2006

1 reference

Expert Opinion on Drug Safety

15 August 2017

1 reference

15 August 2017

5

1 reference

15 August 2017

5

1 reference

15 August 2017

619-629

1 reference

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

15 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Trastuzumab and antiestrogen therapy: focus on mechanisms of action and resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Trastuzumab-associated cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

ErbB2 pathways in heart and neural diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Requirement for neuregulin receptor erbB2 in neural and cardiac development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

ErbB2 is essential in the prevention of dilated cardiomyopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Predicting cancer therapy-induced cardiotoxicity: the role of troponins and other markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.5.5.619

21 January 2018

Identifiers

DOI

10.1517/14740338.5.5.619

1 reference

15 August 2017

1 reference